Who
Ted W. Love
Director
Company insider
Files Form 4 as: Director, Jazz Pharmaceuticals; Director, Structure Therapeutics; Director, Royalty Pharma; Director, Gilead Sciences; Director, Seagen; President and CEO, Global Blood Therapeutics; Director, Portola Pharmaceuticals; Director, Amicus Therapeutics.
In numbers
- Trades disclosed
- 319
- Buys
- 4
- Sells
- 8
- Bought
- $2.3M
- Sold
- $16.7M
- Companies
- 15
- Companies where not an officer
- 12
- First trade
- 1 Aug 2005
- Last trade
- 31 Aug 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1,4646 at $244.06 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $178K737 at $241.39 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $1,4646 at $244.06 | filing |
| 31 Aug 2026filed 2 Sep 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $178K737 at $241.39 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,605 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,453 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code A | —1,146 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,884 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,884 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code A | —1,146 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,527 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —1,527 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | GPCR Structure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,804 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —7,614 at $0.00 | filing |
| 7 May 2025filed 8 May 2025 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,809 at $0.00 | filing |
| 7 May 2025filed 8 May 2025 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code A | —1,516 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.